This report discusses FDA's consideration of the application of its risk-based regulatory framework to the use of AI technologies in drug manufacturing. The authors of the report ask the public to provide feedback after reading this report.
Serving as both a federal and a state depository library, the UNT Libraries Government Documents Department maintains millions of items in a variety of formats. The department is a member of the FDLP Content Partnerships Program and an Affiliated Archive of the National Archives.
Descriptive information to help identify this report.
Follow the links below to find similar items on the Digital Library.
Description
This report discusses FDA's consideration of the application of its risk-based regulatory framework to the use of AI technologies in drug manufacturing. The authors of the report ask the public to provide feedback after reading this report.
This report is part of the following collection of related materials.
Artificial Intelligence (AI) Policy Collection
The Artificial Intelligence (AI) Policy Collection contains open access resources that provide policy overviews, implementation plans, guiding frameworks, and resources for implementing artificial intelligence and machine learning in a wide range of environments. This collection includes documents published by Federal agencies, non-governmental organizations, international, state, and local governments.
United States. Food and Drug Administration.Center for Drug Evaluation and Research: Artificial Intelligence in Drug Manufacturing,
report,
February 28, 2023;
(https://digital.library.unt.edu/ark:/67531/metadc2289514/:
accessed June 10, 2024),
University of North Texas Libraries, UNT Digital Library, https://digital.library.unt.edu;
crediting UNT Libraries Government Documents Department.